-
1
-
-
84859513088
-
Salt and hypertension: is salt dietary reduction worth the effort?
-
Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH. Salt and hypertension: is salt dietary reduction worth the effort? Am J Med. 2012;125(5):433-9
-
(2012)
Am J Med
, vol.125
, Issue.5
, pp. 433-439
-
-
Frisoli, T.M.1
Schmieder, R.E.2
Grodzicki, T.3
Messerli, F.H.4
-
2
-
-
85020504265
-
skin sodium concentration correlates with left ventricular hypertrophy in CKD
-
Schneider MP, RaffU, Kopp C, Scheppach JB, Toncar S, Wanner C, Schlieper G, Saritas T, Floege J, Schmid M, et al. skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol JASN. 2017;28(6):1867-76
-
(2017)
J Am Soc Nephrol JASN
, vol.28
, Issue.6
, pp. 1867-1876
-
-
Schneider, M.P.1
Raff, U.2
Kopp, C.3
Scheppach, J.B.4
Toncar, S.5
Wanner, C.6
Schlieper, G.7
Saritas, T.8
Floege, J.9
Schmid, M.10
-
3
-
-
85042488063
-
Tissue sodium content is increased in type 2 diabetes
-
Kannenkeril DKMV, Jumar A, Ott C, Linz P, Titze J, Uder M, Schmieder RE. Tissue sodium content is increased in type 2 diabetes. Diabetologia. 2017;60:1-608
-
(2017)
Diabetologia
, vol.60
, pp. 1-608
-
-
Kannenkeril, D.K.M.V.1
Jumar, A.2
Ott, C.3
Linz, P.4
Titze, J.5
Uder, M.6
Schmieder, R.E.7
-
4
-
-
84980320178
-
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
-
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-72
-
(2016)
Circulation
, vol.134
, Issue.10
, pp. 752-772
-
-
Heerspink, H.J.1
Perkins, B.A.2
Fitchett, D.H.3
Husain, M.4
Cherney, D.Z.5
-
5
-
-
84994853573
-
Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medicatio
-
Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension (Dallas, Tex: 1979). 2016;68(6):1355-64
-
(2016)
Hypertension (Dallas, Tex: 1979)
, vol.68
, Issue.6
, pp. 1355-1364
-
-
Mancia, G.1
Cannon, C.P.2
Tikkanen, I.3
Zeller, C.4
Ley, L.5
Woerle, H.J.6
Broedl, U.C.7
Johansen, O.E.8
-
6
-
-
84994476908
-
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure
-
Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393-405
-
(2016)
Vasc Health Risk Manag
, vol.12
, pp. 393-405
-
-
Reed, J.W.1
-
7
-
-
84996551945
-
Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
-
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Exp Opin Drug Metab Toxicol. 2016;13:211-23
-
(2016)
Exp Opin Drug Metab Toxicol
, vol.13
, pp. 211-223
-
-
Tomlinson, B.1
Hu, M.2
Zhang, Y.3
Chan, P.4
Liu, Z.M.5
-
8
-
-
85015765803
-
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
-
Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37(42):3192-200
-
(2016)
Eur Heart J
, vol.37
, Issue.42
, pp. 3192-3200
-
-
Marx, N.1
McGuire, D.K.2
-
9
-
-
84928382328
-
Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
-
Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr Hypertens Rep. 2015;17(6):551
-
(2015)
Curr Hypertens Rep
, vol.17
, Issue.6
, pp. 551
-
-
Lovshin, J.A.1
Gilbert, R.E.2
-
10
-
-
67349275999
-
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
-
Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513-9
-
(2009)
Clin Pharmacol Ther
, vol.85
, Issue.5
, pp. 513-519
-
-
Komoroski, B.1
Vachharajani, N.2
Feng, Y.3
Li, L.4
Kornhauser, D.5
Pfister, M.6
-
11
-
-
84941198561
-
Agreement between 24-hour salt ingestion and sodium excretion in a controlled environmen
-
Lerchl K, Rakova N, Dahlmann A, Rauh M, Goller U, Basner M, Dinges DF, Beck L, Agureev A, Larina I, et al. Agreement between 24-hour salt ingestion and sodium excretion in a controlled environment. Hypertension (Dallas, Tex: 1979). 2015;66(4):850-7
-
(2015)
Hypertension (Dallas, Tex: 1979)
, vol.66
, Issue.4
, pp. 850-857
-
-
Lerchl, K.1
Rakova, N.2
Dahlmann, A.3
Rauh, M.4
Goller, U.5
Basner, M.6
Dinges, D.F.7
Beck, L.8
Agureev, A.9
Larina, I.10
-
12
-
-
83655192091
-
(23)Na magnetic resonance imaging of tissue sodiu
-
Kopp C, Linz P, Wachsmuth L, Dahlmann A, Horbach T, SchoflC, Renz W, Santoro D, Niendorf T, Muller DN, et al. (23)Na magnetic resonance imaging of tissue sodium. Hypertension (Dallas, Tex: 1979). 2012;59(1):167-72
-
(2012)
Hypertension (Dallas, Tex: 1979)
, vol.59
, Issue.1
, pp. 167-172
-
-
Kopp, C.1
Linz, P.2
Wachsmuth, L.3
Dahlmann, A.4
Horbach, T.5
Schofl, C.6
Renz, W.7
Santoro, D.8
Niendorf, T.9
Muller, D.N.10
-
13
-
-
84883432973
-
Biomedical applications of sodium MRI in vivo
-
Madelin G, Regatte RR. Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging JMRI. 2013;38(3):511-29
-
(2013)
J Magn Reson Imaging JMRI
, vol.38
, Issue.3
, pp. 511-529
-
-
Madelin, G.1
Regatte, R.R.2
-
14
-
-
0242497268
-
Osmotically inactive skin Na + storage in rats
-
Titze J, Lang R, Ilies C, Schwind KH, Kirsch KA, Dietsch P, Luft FC, Hilgers KF. Osmotically inactive skin Na + storage in rats. Am J Physiol Renal Physiol. 2003;285(6):F1108-17
-
(2003)
Am J Physiol Renal Physiol
, vol.285
, Issue.6
, pp. F1108-F1117
-
-
Titze, J.1
Lang, R.2
Ilies, C.3
Schwind, K.H.4
Kirsch, K.A.5
Dietsch, P.6
Luft, F.C.7
Hilgers, K.F.8
-
15
-
-
0021962777
-
In vivo NMR imaging of sodium-23 in the human head
-
Hilal SK, Maudsley AA, Ra JB, Simon HE, Roschmann P, Wittekoek S, Cho ZH, Mun SK. In vivo NMR imaging of sodium-23 in the human head. J Comput Assist Tomogr. 1985;9(1):1-7
-
(1985)
J Comput Assist Tomogr
, vol.9
, Issue.1
, pp. 1-7
-
-
Hilal, S.K.1
Maudsley, A.A.2
Ra, J.B.3
Simon, H.E.4
Roschmann, P.5
Wittekoek, S.6
Cho, Z.H.7
Mun, S.K.8
-
16
-
-
66749106368
-
Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism
-
Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Muller DN, Derer W, et al. Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15(5):545-52
-
(2009)
Nat Med
, vol.15
, Issue.5
, pp. 545-552
-
-
Machnik, A.1
Neuhofer, W.2
Jantsch, J.3
Dahlmann, A.4
Tammela, T.5
Machura, K.6
Park, J.K.7
Beck, F.X.8
Muller, D.N.9
Derer, W.10
-
17
-
-
77149143546
-
Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rat
-
Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, Eckardt KU, Muller DN, Park JK, Luft FC, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension (Dallas, Tex: 1979). 2010;55(3):755-61
-
(2010)
Hypertension (Dallas, Tex: 1979)
, vol.55
, Issue.3
, pp. 755-761
-
-
Machnik, A.1
Dahlmann, A.2
Kopp, C.3
Goss, J.4
Wagner, H.5
van Rooijen, N.6
Eckardt, K.U.7
Muller, D.N.8
Park, J.K.9
Luft, F.C.10
-
18
-
-
84895484977
-
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
-
Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. DiabetesMetab Res Rev. 2014;30(3):204-21
-
(2014)
DiabetesMetab Res Rev
, vol.30
, Issue.3
, pp. 204-221
-
-
Zhang, M.1
Zhang, L.2
Wu, B.3
Song, H.4
An, Z.5
Li, S.6
-
19
-
-
85013827882
-
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
-
Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 26
-
-
Ott, C.1
Jumar, A.2
Striepe, K.3
Friedrich, S.4
Karg, M.V.5
Bramlage, P.6
Schmieder, R.E.7
-
20
-
-
84892873881
-
Salt intake assessed by 24 h urinary sodium excretion in a random and opportunistic sample in Australia
-
Land MA, Webster J, Christoforou A, Praveen D, Jeffery P, Chalmers J, Smith W, Woodward M, Barzi F, Nowson C, et al. Salt intake assessed by 24 h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open. 2014;4(1):e003720
-
(2014)
BMJ Open
, vol.4
, Issue.1
-
-
Land, M.A.1
Webster, J.2
Christoforou, A.3
Praveen, D.4
Jeffery, P.5
Chalmers, J.6
Smith, W.7
Woodward, M.8
Barzi, F.9
Nowson, C.10
-
21
-
-
0023724346
-
Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group
-
Rose G, Stamler J, Stamler R, Elliott P, Marmot M, Pyorala K, Kesteloot H, Joossens J, Hansson L, Mancia G, Dyer A. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ Clin Res ed. 1988;297(6644):319-28
-
(1988)
BMJ Clin Res ed
, vol.297
, Issue.6644
, pp. 319-328
-
-
Rose, G.1
Stamler, J.2
Stamler, R.3
Elliott, P.4
Marmot, M.5
Pyorala, K.6
Kesteloot, H.7
Joossens, J.8
Hansson, L.9
Mancia, G.10
Dyer, A.11
-
22
-
-
85010202013
-
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
-
Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 8
-
-
Hayashi, T.1
Fukui, T.2
Nakanishi, N.3
Yamamoto, S.4
Tomoyasu, M.5
Osamura, A.6
Ohara, M.7
Yamamoto, T.8
Ito, Y.9
Hirano, T.10
-
23
-
-
85033772700
-
Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
-
Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):149
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 149
-
-
Hayashi, T.1
Fukui, T.2
Nakanishi, N.3
Yamamoto, S.4
Tomoyasu, M.5
Osamura, A.6
Ohara, M.7
Yamamoto, T.8
Ito, Y.9
Hirano, T.10
-
24
-
-
85039561505
-
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
-
Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, Smith DM, Huang Y. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313(5):E563-76
-
(2017)
Am J Physiol Endocrinol Metab
, vol.313
, Issue.5
, pp. E563-E576
-
-
Tang, L.1
Wu, Y.2
Tian, M.3
Sjostrom, C.D.4
Johansson, U.5
Peng, X.R.6
Smith, D.M.7
Huang, Y.8
-
25
-
-
84943187885
-
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
-
Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens. 2015;33(11):2185-97
-
(2015)
J Hypertens
, vol.33
, Issue.11
, pp. 2185-2197
-
-
Imprialos, K.P.1
Sarafidis, P.A.2
Karagiannis, A.I.3
-
26
-
-
85021710250
-
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
-
Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 84
-
-
Shigiyama, F.1
Kumashiro, N.2
Miyagi, M.3
Ikehara, K.4
Kanda, E.5
Uchino, H.6
Hirose, T.7
-
27
-
-
85031924469
-
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
-
Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138
-
(2017)
Cardiovasc Diabetol
, vol.16
, Issue.1
, pp. 138
-
-
Solini, A.1
Giannini, L.2
Seghieri, M.3
Vitolo, E.4
Taddei, S.5
Ghiadoni, L.6
Bruno, R.M.7
-
28
-
-
84995684231
-
Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
-
Scheerer MF, Rist R, Proske O, Meng A, Kostev K. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes Targets Ther. 2016;9:337-45
-
(2016)
Diabetes Metab Syndr Obes Targets Ther
, vol.9
, pp. 337-345
-
-
Scheerer, M.F.1
Rist, R.2
Proske, O.3
Meng, A.4
Kostev, K.5
-
29
-
-
85028958040
-
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study
-
Persson F, Nystrom T, Jorgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13077
-
(2017)
Diabetes Obes Metab
-
-
Persson, F.1
Nystrom, T.2
Jorgensen, M.E.3
Carstensen, B.4
Gulseth, H.L.5
Thuresson, M.6
Fenici, P.7
Nathanson, D.8
Eriksson, J.W.9
Norhammar, A.10
-
30
-
-
84949292797
-
23Na magnetic resonance imaging of the lower leg of acute heart failure patients during diuretic treatment
-
Hammon M, Grossmann S, Linz P, Kopp C, Dahlmann A, Garlichs C, Janka R, Cavallaro A, Luft FC, Uder M, et al. 23Na magnetic resonance imaging of the lower leg of acute heart failure patients during diuretic treatment. PLoS ONE. 2015;10(10):e0141336
-
(2015)
PLoS ONE
, vol.10
, Issue.10
-
-
Hammon, M.1
Grossmann, S.2
Linz, P.3
Kopp, C.4
Dahlmann, A.5
Garlichs, C.6
Janka, R.7
Cavallaro, A.8
Luft, F.C.9
Uder, M.10
-
31
-
-
84874371209
-
23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patient
-
Kopp C, Linz P, Dahlmann A, Hammon M, Jantsch J, Muller DN, Schmieder RE, Cavallaro A, Eckardt KU, Uder M, et al. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension (Dallas, Tex: 1979). 2013;61(3):635-40
-
(2013)
Hypertension (Dallas, Tex: 1979)
, vol.61
, Issue.3
, pp. 635-640
-
-
Kopp, C.1
Linz, P.2
Dahlmann, A.3
Hammon, M.4
Jantsch, J.5
Muller, D.N.6
Schmieder, R.E.7
Cavallaro, A.8
Eckardt, K.U.9
Uder, M.10
-
32
-
-
3042531038
-
Glycosaminoglycan polymerization may enable osmotically inactive Na + storage in the skin
-
Titze J, Shakibaei M, Schafflhuber M, Schulze-Tanzil G, Porst M, Schwind KH, Dietsch P, Hilgers KF. Glycosaminoglycan polymerization may enable osmotically inactive Na + storage in the skin. Am J Physiol Heart Circ Physiol. 2004;287(1):H203-8
-
(2004)
Am J Physiol Heart Circ Physiol
, vol.287
, Issue.1
, pp. H203-H208
-
-
Titze, J.1
Shakibaei, M.2
Schafflhuber, M.3
Schulze-Tanzil, G.4
Porst, M.5
Schwind, K.H.6
Dietsch, P.7
Hilgers, K.F.8
-
33
-
-
0026035348
-
Central role of sodium in hypertension in diabetic subjects
-
Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care. 1991;14(3):220-32
-
(1991)
Diabetes Care
, vol.14
, Issue.3
, pp. 220-232
-
-
Weidmann, P.1
Ferrari, P.2
-
34
-
-
0022160189
-
Pressor factors and responsiveness in hypertension accompanying diabetes mellitu
-
Weidmann P, Beretta-Piccoli C, Trost BN. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension (Dallas, Tex: 1979). 1985;7(6 Pt 2):Ii33-42
-
(1985)
Hypertension (Dallas, Tex: 1979)
, vol.7
, Issue.6
, pp. Ii33-Ii42
-
-
Weidmann, P.1
Beretta-Piccoli, C.2
Trost, B.N.3
-
35
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853-62
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.9
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
36
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28
-
(2015)
N Engl J Med
, vol.373
, Issue.22
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
Mattheus, M.7
Devins, T.8
Johansen, O.E.9
Woerle, H.J.10
-
37
-
-
34047121150
-
Renin-angiotensin system and cardiovascular risk
-
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet (London, England). 2007;369(9568):1208-19
-
(2007)
Lancet (London, England)
, vol.369
, Issue.9568
, pp. 1208-1219
-
-
Schmieder, R.E.1
Hilgers, K.F.2
Schlaich, M.P.3
Schmidt, B.M.4
-
38
-
-
0023680030
-
Dietary salt intake. A determinant of cardiac involvement in essential hypertension
-
Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 1988;78(4):951-6
-
(1988)
Circulation
, vol.78
, Issue.4
, pp. 951-956
-
-
Schmieder, R.E.1
Messerli, F.H.2
Garavaglia, G.E.3
Nunez, B.D.4
-
39
-
-
84894058295
-
Measurement techniques for magnetic resonance imaging of fast relaxing nuclei
-
Konstandin S, Nagel AM. Measurement techniques for magnetic resonance imaging of fast relaxing nuclei. Magma (New York, NY). 2014;27(1):5-19
-
(2014)
Magma (New York, NY)
, vol.27
, Issue.1
, pp. 5-19
-
-
Konstandin, S.1
Nagel, A.M.2
-
40
-
-
84913613613
-
Skin sodium measured with (2)(3)Na MRI at 7.0 T
-
Linz P, Santoro D, Renz W, Rieger J, Ruehle A, RuffJ, Deimling M, Rakova N, Muller DN, Luft FC, et al. Skin sodium measured with (2)(3)Na MRI at 7.0 T. NMR Biomed. 2015;28(1):54-62
-
(2015)
NMR Biomed
, vol.28
, Issue.1
, pp. 54-62
-
-
Linz, P.1
Santoro, D.2
Renz, W.3
Rieger, J.4
Ruehle, A.5
Ruff, J.6
Deimling, M.7
Rakova, N.8
Muller, D.N.9
Luft, F.C.10
-
41
-
-
85018382982
-
3 Tesla 23Na Magnetic Resonance Imaging During Acute Kidney Injury
-
Hammon M, Grossmann S, Linz P, Seuss H, Hammon R, Rosenhauer D, Janka R, Cavallaro A, Luft FC, Titze J, et al. 3 Tesla 23Na Magnetic Resonance Imaging During Acute Kidney Injury. Acad Radiol. 2017;24(9):1086-93
-
(2017)
Acad Radiol
, vol.24
, Issue.9
, pp. 1086-1093
-
-
Hammon, M.1
Grossmann, S.2
Linz, P.3
Seuss, H.4
Hammon, R.5
Rosenhauer, D.6
Janka, R.7
Cavallaro, A.8
Luft, F.C.9
Titze, J.10
|